'The lights are no longer green': Antitrust regulators reassess pharma deals
BioPharma
Stay updated with breaking news from Bruce Booth. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Nimbus Therapeutics, a biotechnology company designing breakthrough medicines through structure-based drug discovery and development, announced it has appointed Anne McGeorge, M.S., CPA, to its Board of Directors, and as Audit Committee Chair. Ms. McGeorge is a seasoned finance executive with decades of experience advising healthcare and life sciences organizations. “On behalf of Nimbus’ leadership team and Board, I am delighted to welcome Anne McGeorge to our Board of Directors. Anne’s technical acumen across all areas of finance for both private and public companies will be an asset t...
iStock; Skye Gould/Insider This story is available exclusively to Insider subscribers. Become an Insider and start reading now. At least 6 biotech startups launched in the past year after creating or acquiring smaller ventures. These "mega biotechs" are fueled by record amounts of VC flowing into the drug industry. Insiders say they are "priced for perfection" and could fail to live up to their early valuations. To understand the hottest new trend in biotech, take a look at the firm Centessa Pharmaceuticals. Centessa was form...
This story is available exclusively to Insider subscribers. Become an Insider and start reading now. The FDA approved BridgeBio's first drug, for a disease that affects 100 children in the US and Europe. BridgeBio mitigates risk with a "hub-and-spoke" model, with a central management team and subsidiaries. The model is gaining in popularity in biopharma and could reshape drug R&D, McKinsey & Co. says. It wasn't that long ago that the idea behind BridgeBio drew laughter from biotech and finance experts. But these days, CEO Neil Kumar says he's taking calls...
âWhen the spotlight found Moderna, they were readyâ: How the Cambridge biotech company became a world renowned success story By Scott Kirsner Globe Correspondent,Updated December 18, 2020, 7:11 p.m. Email to a Friend A year ago, Moderna was not on anyoneâs âMost Likely to Succeedâ list. As the Cambridge biotech approached its 10th year, the company had yet to get a single product approved for sale by government regulators. Investors werenât particularly hot on its potential, either â after going public in December 2018, Modernaâs stock price hadnât...